The 24,000m² facility can reconfigure rapidly for the production of up to four different products simultaneously Sanofi has announced the inauguration of its new modular vaccine and biomedicine production unit Its standardised mini-factories equipped with interconnected modular equipment allow the 24,000m² facility to adapt and reconfigure rapidly for the production of up to four different products simultaneously Modulus can also rapidly reconfigure itself to switch technological platforms such as live attenuated viral vaccines or messenger RNA vaccines and treatments created from biotechnologies such as enzymes or monoclonal antibodies The plant was established with €500m funding and will be operational by the end of 2025 Sanofi CEO Paul Hudson stated: “The creation of Modulus is one of our greatest prides the result of Sanofi’s unique industrial know-how but a revolution in the way we will manufacture vaccines and biomedicines in the coming decades Don’t let policy changes catch you off guard Stay proactive with real-time data and expert analysis from the design of the building to the way we collaborate with health authorities to imagine a factory that will be best able to meet the health challenges of patients in France and around the world Sanofi offers France and Europe unrivalled leadership in health sovereignty.” The inauguration of the facility follows a recent announcement of more than €1bn investment aimed at doubling monoclonal antibody production at the Vitry-sur-Seine site and enhancing active ingredient production in southern France The latest development comes after Sanofi and Vir Biotechnology concluded an exclusive worldwide licence agreement for multiple clinical-stage T-cell engagers Give your business an edge with our leading industry insights View all newsletters from across the GlobalData Media network Sanofi is planning to build a new Evolutive vaccine facility (EVF) for the manufacturing of vaccines in Neuville-sur-Saône in the eastern part of France to supply vaccines in case of new pandemics The investment will boost the company’s capability to further research and mass production of new innovative vaccines The project will involve an investment of €490m ($552.4m) over five years and create 200 new job opportunities Sanofi’s Evolutive vaccine manufacturing facility will be located in the Neuville-sur-Saône commune of France The Neuville-sur-Saône site is located close to the company’s facility in Marcy-l’Etoile as well as the Genzyme production site of Sanofi situated in the centre of the Sanofi Biotechnology Hub in the city of Lyon The company’s existing operations at the facility in Neuville-sur-Saône primarily include biotechnological manufacturing of vaccines The Neuville-sur-Saône site represents the first dengue vaccine production centre in the world In addition, the site includes a research and development (R&D) laboratory devoted to analytical sciences The plant has high-tech facilities and an innovative structure that enables new vaccines to be developed in collaboration with R&D The state-of-the-art manufacturing facility will incorporate the latest advanced technologies for the manufacturing of vaccines EVF is a facility built around a central unit that includes completely digital production modules The modern factory will be able to produce three to four vaccines at the same time compared to only one in the existing sites Customisation and modular design will enable the development of a specific vaccine on priority and in a more reasonable time frame depending on public health concerns Sanofi will work with the European Union (EU) and the French Government to create an additional vaccine or monoclonal antibody (installation of cell culture tanks and start-up projects) manufacturing capabilities for the EU and pharmaceutical firms in case of any healthcare emergency Sanofi is a major healthcare company delivering solutions and services in more than 170 countries around the world It plays an instrumental part in meeting customers’ healthcare demands and improving health services Through its global vaccines division Sanofi Pasteur, Sanofi is involved in the development and manufacturing of vaccines The multinational company’s vaccine portfolio includes products to treat patients from infectious diseases Sanofi Pasteur employs 16,000 personnel and operates 12 vaccine manufacturing sites medicines and healthcare-related drug products in France It has 33 sites in France including 22 industrial sites The company has around 5,000 scientists and researchers engaged in therapy areas It is also planning to spend €120m ($135.3m) to set up a new research and development facility in France at Sanofi Pasteur’s Marcy-l’Etoile site to produce possible future vaccines The proposed advanced digital facility in Marcy-l’Etoile will be equipped with specialised laboratories for vaccine development against emerging diseases and pandemic hazards Sanofi aims to transform its French operations into a centre of excellence in the areas of vaccine research and manufacturing The company is also supporting global efforts to combat the Covid-19 pandemic disease It joined forces with GSK to explore the use of recombinant DNA technology to produce a potential Covid-19 vaccine are focused on developing a vaccine using messenger RNA technology The Arkema platform in Genay is made up of a production unit and an R&D center These two entities work together to optimize the manufacturing of rheological additives it was fully integrated into the Swiss group OMYA which is still one of our privileged customers to this day the site acquired a new dispersing agent manufacturing workshop The site in Genay became a full Arkema subsidiary in October 2007 five years before increasing its thickening agent production capacity through debottlenecking The 12 hectares of the  platform are located in Genay A research and development department With a total workforce of between 230 and 250 people the platform in Genay exports 70 to 100 kt of finished products 90% of which are for international markets Other products are used in building materials Always at the forefront in terms of safety and the environment As part of the Common Ground® program the site in Genay conducts awareness-raising actions for elected officials All of Genay's employees gathered to celebrate the 50th anniversary of their factory for a convivial moment It was also an opportunity to remember the path taken by the site which opened in December 1971 as a local additives plant for the paper industry. Today being the Arkema’s core expertise Center in Rheology and Specialty Additive the extended reach of the activity across the world includes five industrial plants and four R&D and application centers Under the provisions of decree No. 2019–15 of January 8, 2019 at eliminating the differences in compensation between men and women achieved a result of 88 out of 100 for the reference year 2024 which expands their long-standing collaboration in life sciences and healthcare will leverage virtual twin experiences to enable agile and flexible operations that advance Sanofi’s ambition to secure its product portfolio Sanofi will use Dassault Systèmes’ “Made to Cure for BioPharma” industry solution experience based on the 3DEXPERIENCE platform to design qualify and operate modular production lines at the two “EVolutive Facilities.” These will rely on single-use technology and mobile equipment to manufacture up to four products simultaneously and sustainably by selecting the most advanced technologies to reduce their energy consumption The platform provides a virtual environment for collaborative innovation and end-to-end data management across the life cycle  Sanofi can experience the manufacturing systems under development and their operation virtually and optimize scale up and industrialization processes before deploying them “We want to improve people’s lives by giving them faster access to vaccines and treatments while minimizing the environmental impacts of our activities,” said Ana Alves EVolutive Facility Global Project Head & Site Head of Neuville sur Saone “Dassault Systèmes delivers the technology we need to accelerate the introduction of new products in the facility by supporting the collaborative works of our teams and by strengthening the standardization of designs and models It will also bring capabilities to reach our objective to produce several products in the EVF in an optimized schedule the 3DEXPERIENCE platform will help us to address the complexity of the product lifecycle management in a highly regulated environment and for the benefit of our patients.” Pharmaceutical manufacturers must qualify facilities equipment and processes before production to ensure safety and quality  This can take weeks or months depending on the equipment configurations and process parameters for different product recipes  Virtual twins enable manufacturers to standardize modules and boost their ability to quickly and massively produce crucial therapies Sanofi can visualize and simulate the recipe equipment and consumables that a particular process requires as well as the flow and activity of the modules and operators in the “ballroom” – a flexible and adaptable area that enables manufacturers to quickly switch between processes remove and replace functional elements and process steps as needed in a seamless way and reconfigure the production lines for a fast changeover from one product to another one  It can also accelerate the main activities of the life cycle of new modules processes and facilities more quickly and catalog them into its product life cycle management for reuse and faster product changeover “The pandemic made it clear: BioPharmas must be able to maximize efficiency and quickly provide high-quality innovative therapeutics to patients worldwide,” said Claire Biot “Sanofi is responding to this challenge with next generation modular manufacturing that can transform the speed at which products reach patients Sanofi will implement new products right the first time with faster production ramp-ups and concurrent process production for built-in flexibility Ergonomics on the shop floor can be simulated and improved.”  About us | Advertise with us | Contact us The pharmaceutical company shared that its new investment adds to the current €2.5 billion planned for major building projects in France Using an investment of over €1 billion, Sanofi plans to generate new bioproduction capacity at three sites in France The sites are in Vitry-sur-Seine (Val de Marne) Le Trait (Seine-Maritime) and Lyon Gerland (Rhône) This cash injection will create more than 500 jobs and “significantly strengthen” France’s present and future ability to control the full production process of essential medicines, the company stated A total of €1 billion will be used to construct a new facility In Vitry-sur-Seine Sanofi explained that it will “double the site’s monoclonal antibody production capacity” The cash injection will create more than 500 jobs and “significantly strengthen” France’s present and future ability to control the full production process of essential medicines” The Vitry facility could produce several potential blockbuster biologics currently in development Sanofi expects that 350 jobs will be created at the facility following this investment Sanofi added that it will devote €100 million for new capacity for biologics formulation This will help support launch of future biologics and vaccines, as well as the continued growth of Dupixent®; which could become the first biologic to treat chronic obstructive pulmonary disease (COPD) In Lyon Gerland, Sanofi stated that it is investing €10 million to locate production of TZield® Audrey Derveloy President of Sanofi France commented that the company chose the Vitry site “to double its monoclonal antibody production capacity after having already invested heavily in Neuville-sur-Saône to produce [its] future vaccines We have also strengthened our API production sites in the south of France” Sanofi also shared that other major projects launched in France to support the country’s production capacity of new drugs and vaccines include: By No comments yet All subscriptions include online membership giving you access to the journal and exclusive content Comment *document.getElementById("comment").setAttribute( "id" "a65eb9d6f886bdec4fdefea1db53c1f0" );document.getElementById("a9d92917df").setAttribute( "id" Write for us | Advertise with us European Pharmaceutical Review is published by: Russell Publishing Ltd.Court LodgeHogtrough HillBrasted © Russell Publishing Limited Website development by e-Motive Media Limited Necessary cookies are absolutely essential for the website to function properly This category only includes cookies that ensures basic functionalities and security features of the website These cookies do not store any personal information CookieDescriptioncookielawinfo-checkbox-advertising-targetingThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".cookielawinfo-checkbox-analyticsThis cookie is set by GDPR Cookie Consent WordPress Plugin The cookie is used to remember the user consent for the cookies under the category "Analytics".cookielawinfo-checkbox-necessaryThis cookie is set by GDPR Cookie Consent plugin The cookie is used to store the user consent for the cookies in the category "Necessary".cookielawinfo-checkbox-performanceThis cookie is set by GDPR Cookie Consent WordPress Plugin The cookie is used to remember the user consent for the cookies under the category "Performance".PHPSESSIDThis cookie is native to PHP applications The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website The cookie is a session cookies and is deleted when all the browser windows are closed.viewed_cookie_policyThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies It does not store any personal data.zmember_loggedThis session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users A DAD is understood to have been killed in front of his kids when a fairground ride collapsed which spins its occupants around in groups of two crashed to the ground in France early on Saturday evening in Neuville-sur-Saone Multiple people hit the ground after they were thrown from their “pods” He is believed to be a 40-year-old father who was at the fair with his two children Four children were also injured in the accident including an eight-year-old boy who was taken to hospital to be treated for serious wounds blamed a technical fault for the tragic accident He told French radio: “The carousel fell suddenly and hit the ground hard.” An investigation has been launched to determine the cause of the accident The ride consisted of 14 “cars” that circled a central rotating carousel spinning people around and lifting them up and down in groups of two The fair was closed after the accident and police were seen attending the site Last year, a 12-year-old boy near Liverpool fractured his skull after he was thrown from a fairground ride. He was left with traumatic injuries and underwent a four-hour surgery Shortly after, six British theme parks were forced to close their pendulum-style rides after an 18-year-old American was thrown from one 30 feet into the air He died after the ride malfunctioned and his carriage crashed into the ground We pay for your stories! Do you have a story for The Sun Online news team? Email us at tips@the-sun.co.uk or call 0207 782 4368 . You can WhatsApp us on 07810 791 502. We pay for videos too. Click here to upload yours Our journalists strive for accuracy but on occasion we make mistakes. For further details of our complaints policy and to make a complaint please click this link: thesun.co.uk/editorial-complaints/